JP2019501133A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501133A5 JP2019501133A5 JP2018526682A JP2018526682A JP2019501133A5 JP 2019501133 A5 JP2019501133 A5 JP 2019501133A5 JP 2018526682 A JP2018526682 A JP 2018526682A JP 2018526682 A JP2018526682 A JP 2018526682A JP 2019501133 A5 JP2019501133 A5 JP 2019501133A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- formula
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 62
- 150000003839 salts Chemical class 0.000 claims description 32
- 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- -1 cyano, hydroxy Chemical group 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims description 10
- 239000004012 Tofacitinib Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 229960001350 tofacitinib Drugs 0.000 claims description 8
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 6
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 6
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 206010009887 colitis Diseases 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000000651 prodrug Substances 0.000 claims description 6
- 229940002612 prodrug Drugs 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 102000053187 Glucuronidase Human genes 0.000 claims description 4
- 108010060309 Glucuronidase Proteins 0.000 claims description 4
- 210000001072 colon Anatomy 0.000 claims description 4
- 229930182480 glucuronide Natural products 0.000 claims description 4
- 150000008134 glucuronides Chemical class 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- KYIOVQZVBFQNEB-UHFFFAOYSA-N 3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound OC1COC(C(O)=O)C(O)C1O KYIOVQZVBFQNEB-UHFFFAOYSA-N 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 7
- 0 C[C@](CCN(C1)C(CC#N)=O)[C@]1N(C)c1c(cc[n]2C(N(C)CCN(C)C(OCc(cc3)cc(*)c3O[C@@]([C@]([C@@]([C@@]3O)O)O)O[C@@]3C(O)=O)=O)=O)c2ncn1 Chemical compound C[C@](CCN(C1)C(CC#N)=O)[C@]1N(C)c1c(cc[n]2C(N(C)CCN(C)C(OCc(cc3)cc(*)c3O[C@@]([C@]([C@@]([C@@]3O)O)O)O[C@@]3C(O)=O)=O)=O)c2ncn1 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 5
- NKJXNCPMTBJPHR-BEFAXECRSA-N C[C@H](CCN(C1)C(CC#N)=O)[C@H]1N(C)c1ncnc2c1cc[n]2C(Oc(cc1)ccc1[N+]([O-])=O)=O Chemical compound C[C@H](CCN(C1)C(CC#N)=O)[C@H]1N(C)c1ncnc2c1cc[n]2C(Oc(cc1)ccc1[N+]([O-])=O)=O NKJXNCPMTBJPHR-BEFAXECRSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562259273P | 2015-11-24 | 2015-11-24 | |
| US62/259,273 | 2015-11-24 | ||
| PCT/US2016/063254 WO2017091544A1 (en) | 2015-11-24 | 2016-11-22 | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020141651A Division JP2020196742A (ja) | 2015-11-24 | 2020-08-25 | 胃腸炎症性腸疾患の処置のための、ｊａｋ阻害剤化合物のプロドラッグ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501133A JP2019501133A (ja) | 2019-01-17 |
| JP2019501133A5 true JP2019501133A5 (enExample) | 2019-11-14 |
| JP6778747B2 JP6778747B2 (ja) | 2020-11-04 |
Family
ID=57518004
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018526682A Active JP6778747B2 (ja) | 2015-11-24 | 2016-11-22 | 胃腸炎症性腸疾患の処置のための、ｊａｋ阻害剤化合物のプロドラッグ |
| JP2020141651A Pending JP2020196742A (ja) | 2015-11-24 | 2020-08-25 | 胃腸炎症性腸疾患の処置のための、ｊａｋ阻害剤化合物のプロドラッグ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020141651A Pending JP2020196742A (ja) | 2015-11-24 | 2020-08-25 | 胃腸炎症性腸疾患の処置のための、ｊａｋ阻害剤化合物のプロドラッグ |
Country Status (33)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10556901B2 (en) | 2015-11-03 | 2020-02-11 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as Janus kinase inhibitors |
| ES2864035T3 (es) | 2015-11-03 | 2021-10-13 | Topivert Pharma Ltd | Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina y 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inhibidores de la quinasa janus |
| BR112018010650A8 (pt) | 2015-11-24 | 2019-02-26 | Theravance Biopharma R&D Ip Llc | pró-fármacos de um inibidor de jak composto para o tratamento da doença inflamatória gastrointestinal |
| FR3060567B1 (fr) * | 2016-12-19 | 2019-05-24 | Ecole Normale Superieure De Lyon | Substrat de glycosidase fluorogene et procede de detection associe |
| US10472366B2 (en) | 2017-03-08 | 2019-11-12 | Theravance Biopharma R&D Ip, Llc | Glucuronide prodrugs of tofacitinib |
| BR112019024509A2 (pt) | 2017-05-23 | 2020-06-23 | Theravance Biopharma R&D Ip, Llc | Glicuronídeo de pró-fármacos dos inibidores da janus quinase |
| CN110662755A (zh) * | 2017-05-23 | 2020-01-07 | 施万生物制药研发Ip有限责任公司 | 托法替尼的硫代氨基甲酸酯前药 |
| KR20200011972A (ko) * | 2017-06-05 | 2020-02-04 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 멀티바이오틱제 및 이를 사용하는 방법 |
| PE20211305A1 (es) | 2018-01-05 | 2021-07-20 | Cybrexa 1 Inc | Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas |
| KR20190110459A (ko) * | 2018-03-20 | 2019-09-30 | 삼진제약주식회사 | 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물 |
| WO2019246273A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor |
| WO2020034987A1 (zh) * | 2018-08-15 | 2020-02-20 | 江苏豪森药业集团有限公司 | 含有葡糖苷酸衍生物jak抑制剂的前药及其制备方法和应用 |
| KR102836433B1 (ko) * | 2018-09-06 | 2025-07-21 | 아레나 파마슈티칼스, 인크. | 자가면역 및 염증성 장애의 치료에 유용한 화합물 |
| CN109134564B (zh) * | 2018-09-21 | 2022-03-11 | 合肥锐思生物医药有限公司 | 乳果糖糖苷衍生物、其制备方法及其用途 |
| EA202191354A1 (ru) * | 2018-11-15 | 2021-08-11 | Янссен Байотек, Инк. | Способы и композиции для прогнозирования ответа на терапию воспалительного заболевания кишечника |
| TWI884142B (zh) * | 2018-12-19 | 2025-05-21 | 美商英塞特公司 | 用於治療胃腸道疾病之jak1路徑抑制劑 |
| CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
| CA3146560A1 (en) | 2019-07-10 | 2021-01-14 | Cybrexa 2, Inc. | Peptide conjugates of cytotoxins as therapeutics |
| CA3146385A1 (en) | 2019-07-10 | 2021-01-14 | Cybrexa 3, Inc. | Peptide conjugates of microtubule-targeting agents as therapeutics |
| US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021097074A1 (en) * | 2019-11-13 | 2021-05-20 | New York University | Intestinal organoid co-culture systems and methods for treating or preventing a disease or disorder associated with immune response-mediated tissue injury |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2021174024A1 (en) * | 2020-02-28 | 2021-09-02 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| TW202207918A (zh) | 2020-05-14 | 2022-03-01 | 美商施萬生物製藥研發Ｉｐ有限責任公司 | 腸道選擇性ｊａｋ３抑制劑的投與 |
| CN113943312A (zh) * | 2020-07-17 | 2022-01-18 | 轶诺(浙江)药业有限公司 | 一类肠道裂解型共药及其制备和用途 |
| US20250325662A1 (en) * | 2020-10-22 | 2025-10-23 | Bt Bidco, Inc. | Methods of treating and predicting non-response to anti-tnf treatment in subjects with gastrointestinal tract diseases |
| WO2022260945A1 (en) * | 2021-06-07 | 2022-12-15 | The Regents Of The University Of California | Compositions and methods for treating celiac disease |
| CN117355527B (zh) * | 2021-07-20 | 2024-06-07 | 上海椿安生物医药科技有限公司 | 一种消炎偶联化合物药物及其制法和应用 |
| JP2025516712A (ja) * | 2022-05-14 | 2025-05-30 | 株式会社スリー・ディー・マトリックス | 消化管への治療剤の経口投与のための新規な製剤 |
| CN115073543B (zh) * | 2022-07-20 | 2022-11-15 | 北京普祺医药科技股份有限公司 | 一种jak抑制剂的化合物前药及其制备与应用 |
| CN117567460A (zh) * | 2022-08-08 | 2024-02-20 | 明慧医药（杭州）有限公司 | 一种前药化合物及其制备方法和用途 |
| CA3264418A1 (en) | 2022-08-17 | 2024-02-22 | Transcend Therapeutics, Inc. | PRECURSORS OF PHENETHYLAMINES AND CATHINONES |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993022334A1 (en) | 1992-05-04 | 1993-11-11 | Sri International | Pharmaceutical compositions and methods for colonic delivery of corticosteroids |
| US5811388A (en) | 1995-06-07 | 1998-09-22 | Cibus Pharmaceutical, Inc. | Delivery of drugs to the lower GI tract |
| AU777911B2 (en) | 1999-12-10 | 2004-11-04 | Pfizer Products Inc. | Pyrrolo(2,3-d)pyrimidine compounds |
| KR101805936B1 (ko) | 2009-10-09 | 2017-12-07 | 인사이트 홀딩스 코포레이션 | 3-（4-（7Ｈ-피롤로〔2,3-ｄ〕피리미딘-4-일）-1Ｈ-피라졸-1-일）-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체 |
| EP2695617B1 (en) | 2009-12-23 | 2019-01-09 | Glycomyr Inc. | Vitamin D glycosides and sulfates for treating intestinal diseases |
| WO2011082368A2 (en) | 2009-12-31 | 2011-07-07 | Enzon Pharmaceuticals, Inc | Polymeric conjugates of aromatic amine containing compounds including releasable urea linker |
| MX2012009074A (es) * | 2010-02-05 | 2012-08-23 | Pfizer | Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa. |
| US20130109720A1 (en) | 2011-11-01 | 2013-05-02 | Hoffmann-La Roche Inc. | Indole inhibitors of crac |
| AU2014273983A1 (en) * | 2013-05-31 | 2015-12-17 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for the therapeutic delivery |
| JP6697403B2 (ja) * | 2014-06-24 | 2020-05-20 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 炎症性腸疾患の処置のための方法及び医薬組成物 |
| BR112018010650A8 (pt) | 2015-11-24 | 2019-02-26 | Theravance Biopharma R&D Ip Llc | pró-fármacos de um inibidor de jak composto para o tratamento da doença inflamatória gastrointestinal |
| EP3394080B1 (en) | 2015-12-23 | 2023-06-07 | The University Of British Columbia | Lipid-linked prodrugs |
| CN106496233B (zh) | 2016-09-26 | 2018-05-15 | 东南大学 | 吡咯并嘧啶类化合物、其制备方法及其用途 |
-
2016
- 2016-11-22 BR BR112018010650A patent/BR112018010650A8/pt not_active IP Right Cessation
- 2016-11-22 KR KR1020187017879A patent/KR20180080330A/ko not_active Withdrawn
- 2016-11-22 DK DK16808876.3T patent/DK3380486T3/da active
- 2016-11-22 SM SM20200242T patent/SMT202000242T1/it unknown
- 2016-11-22 PT PT168088763T patent/PT3380486T/pt unknown
- 2016-11-22 HR HRP20200561TT patent/HRP20200561T1/hr unknown
- 2016-11-22 TW TW105138180A patent/TWI703147B/zh not_active IP Right Cessation
- 2016-11-22 SI SI201630741T patent/SI3380486T1/sl unknown
- 2016-11-22 EA EA201891248A patent/EA035816B1/ru unknown
- 2016-11-22 UA UAA201806963A patent/UA121270C2/uk unknown
- 2016-11-22 MY MYPI2018701637A patent/MY189979A/en unknown
- 2016-11-22 SG SG11201803686UA patent/SG11201803686UA/en unknown
- 2016-11-22 JP JP2018526682A patent/JP6778747B2/ja active Active
- 2016-11-22 ME MEP-2020-126A patent/ME03757B/me unknown
- 2016-11-22 RS RS20200508A patent/RS60237B1/sr unknown
- 2016-11-22 WO PCT/US2016/063254 patent/WO2017091544A1/en not_active Ceased
- 2016-11-22 ES ES16808876T patent/ES2784523T3/es active Active
- 2016-11-22 AU AU2016359494A patent/AU2016359494B2/en not_active Ceased
- 2016-11-22 CN CN201680068165.XA patent/CN108290918B/zh active Active
- 2016-11-22 HU HUE16808876A patent/HUE049775T2/hu unknown
- 2016-11-22 US US15/358,462 patent/US10435428B2/en active Active
- 2016-11-22 CA CA3003283A patent/CA3003283A1/en not_active Abandoned
- 2016-11-22 PL PL16808876T patent/PL3380486T3/pl unknown
- 2016-11-22 NZ NZ742574A patent/NZ742574A/en not_active IP Right Cessation
- 2016-11-22 MX MX2018006282A patent/MX383107B/es unknown
- 2016-11-22 EP EP16808876.3A patent/EP3380486B1/en active Active
- 2016-11-22 LT LTEP16808876.3T patent/LT3380486T/lt unknown
-
2018
- 2018-05-01 IL IL259076A patent/IL259076B/en active IP Right Grant
- 2018-05-07 ZA ZA2018/02967A patent/ZA201802967B/en unknown
- 2018-05-15 PH PH12018501037A patent/PH12018501037A1/en unknown
- 2018-05-18 CL CL2018001345A patent/CL2018001345A1/es unknown
- 2018-05-22 CO CONC2018/0005327A patent/CO2018005327A2/es unknown
-
2019
- 2019-08-29 US US16/555,222 patent/US10961267B2/en active Active
-
2020
- 2020-05-13 CY CY20201100447T patent/CY1122918T1/el unknown
- 2020-08-25 JP JP2020141651A patent/JP2020196742A/ja active Pending
-
2021
- 2021-02-22 US US17/249,126 patent/US11608354B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019501133A5 (enExample) | ||
| KR102488479B1 (ko) | 인플루엔자 바이러스 감염에 사용하기 위한 인돌 | |
| JP6716785B2 (ja) | Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物 | |
| CN107207498B (zh) | 用于治疗hiv的稠合嘧啶化合物 | |
| TWI649308B (zh) | 喹啉衍生物 | |
| JP2014511892A5 (enExample) | ||
| CA3163424A1 (en) | Methods for treating sars cov-2 infections | |
| JP2016534063A5 (enExample) | ||
| HRP20200561T1 (hr) | Prolijekovi spoja jak inhibitora za liječenje gastrointestinalnih upalnih bolesti | |
| TW201927771A (zh) | 可作為蛋白質調節劑之雜環醯胺及其使用方法 | |
| JP2012524056A5 (enExample) | ||
| JP2015511638A5 (enExample) | ||
| JP2017518334A5 (enExample) | ||
| JP2013518107A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP2013544846A5 (enExample) | ||
| JP2011529071A5 (enExample) | ||
| JP2016506962A5 (enExample) | ||
| US20220001015A1 (en) | Lymphatic system-directing lipid prodrugs | |
| JP2013510123A5 (enExample) | ||
| JP2013519645A5 (enExample) | ||
| JP2017531619A5 (enExample) | ||
| JP2017526677A5 (enExample) | ||
| JP2023547599A (ja) | リン脂質化合物及びその使用 |